ArticleInsights into imaging2026
Preoperative contrast-enhanced CT prediction of distinct vascular patterns in solitary early-stage hepatocellular carcinoma and its prognostic value.
Article in Insights into imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectivesTo investigate the value of qualitative and quantitative contrast-enhanced CT (CECT) features for noninvasive identification of two distinct vascular patterns, vessels that encapsulate tumor clusters (VETC) and/or microvascular invasion (MVI), in solitary early-stage (BCLC 0-A) hepatocellular carcinoma (HCC) and assess their prognostic implications. MATERIALS AND
methodsWe retrospectively included 347 patients with solitary early-stage HCC who underwent preoperative CECT and subsequent resection at two centers. Patients were divided into V/M+ (MVI and/or VETC positive, n = 174) and VM- (both MVI and VETC negative, n = 173) groups based on histopathology. Four predictive models (clinical, CT quantitative, CT qualitative, and combined) integrating clinical and CECT features were developed and validated for identifying V/M+ status. The optimal model was further applied to predict 2-year recurrence-free survival (RFS). Sensitivity analysis was performed using propensity score matching (PSM). Models' performance was evaluated and compared using AUC analyses and DeLong tests.
resultsThe combined model [serum AFP ≥ 200 ng/mL, non-smooth tumor margin, internal arteries, and lower tumor-to-liver density ratio in the portal venous phase (P-TLR)] achieved optimal predictive performance for V/M + HCC, with training AUC of 0.784 and 0.782 pre- and post-PSM, and external validating AUC of 0.794. A derived V/M+ score stratified patients, with higher scores associated with significantly shorter 2-year RFS. V/M+ score ≥ 34 and tumor size ≥ 60 mm were significant predictors of HCC recurrence (p < 0.05).
conclusionThe combined model integrating clinical and CECT-based features, enables non-invasive assessment of V/M status in early-stage solitary HCC and effectively stratifies patients according to recurrence risk. CRITICAL RELEVANCE STATEMENT: Specific CT-based qualitative and quantitative features are associated with a distinct vascular pattern of BCLC stage 0-A HCC. The developed combined model and derived V/M+ score offer a reliable tool for clinicians to predict V/M + HCC and patients' 2-year RFS. KEY POINTS: Specific CECT-based qualitative and quantitative features are associated with V/M + HCC at the BCLC stage 0-A. The developed combined model offers a reliable tool for clinicians to identify V/M + HCC. The derived V/M+ score helps stratify HCC patients into high- and low-risk groups for 2-year RFS, facilitating personalized management of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.